CLDN18.2: A New Beacon of Hope in Pancreatic Cancer Treatment
21/06/2026
CLDN18.2 has become one of the most promising therapeutic targets in pancreatic cancer. From bispecific antibodies and antibody-drug conjugates to CAR-T cell therapy, researchers are exploring innovative approaches that could transform treatment options for patients with this difficult-to-treat disease.